Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | ESR1 | P03372 | 4/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | TACR2 | P21452 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SHBG | P04278 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Octanol SCHEMBL2363951 | 0.91 | LMNA (0.54) | ACHEALDH1A1ESR1ADRA2AADORA3 | |
| P-Xylene SCHEMBL3200566 | 0.91 | ALDH1A1 (0.61) | ACHEALDH1A1HSD17B10LMNAMEN1 | |
| P-Xylene SCHEMBL10683034 | 0.88 | ALDH1A1 (0.58) | ACHEALDH1A1HSD17B10LMNAMEN1 | |
| P-Cresol SCHEMBL11600098 | 0.88 | ACHE (0.68) | ACHEALDH1A1ESR1ADRA2AADORA3 | |
| Octanol SCHEMBL4641838 | 0.86 | NR5A1 (0.50) | ACHEALDH1A1ESR1ADRA2AADORA3 | |
| Octane SCHEMBL11602147 | 0.86 | ACHE (0.65) | ACHEALDH1A1ESR1ADRA2AADORA3 | |
| P-Xylene SCHEMBL11202857 | 0.86 | ALDH1A1 (0.55) | ACHEALDH1A1HSD17B10LMNAMEN1 | |
| Dodecane SCHEMBL28591401 | 0.86 | ACHE (0.65) | ACHEALDH1A1ESR1ADRA2AADORA3 | |
| Nonane SCHEMBL27776640 | 0.86 | ACHE (0.65) | ACHEALDH1A1ESR1ADRA2AADORA3 | |
| P-Cresol SCHEMBL6767262 | 0.83 | ACHE (0.77) | ACHEALDH1A1ESR1ADRA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2632453-A1 | NITRIC OXIDE AMINO ACID ESTERS FOR IMPROVING VASCULAR CIRCULATION, AND PROPHYLAXIS OR TREATMENT OF A CONDITION ASSOCIATED WITH IMPAIRED BLOOD CIRCULATION | Oral Delivery Technology Ltd. (CA) | 2013-09-04 | — | — | EP | claimed |
| WO-2012088597-A1 | NITRIC OXIDE AMINO ACID ESTERS FOR ENHANCEMENT OF PHYSICAL OR MUSCULAR PERFORMANCE AND THE TREATMENT OF MUSCULAR OR NEUROMUSCULAR DISEASES | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2012-07-05 | — | — | WO | claimed |
| WO-2012079146-A1 | NITRIC OXIDE AMINO ACID ESTERS FOR IMPROVING VASCULAR CIRCULATION, AND PROPHYLAXIS OR TREATMENT OF A CONDITION ASSOCIATED WITH IMPAIRED BLOOD CIRCULATION | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2012-06-21 | — | — | WO | claimed |
| WO-2012027827-A1 | NITRIC OXIDE AMINO ACID ESTERS FOR SKIN REJUVENATION | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2012-03-08 | — | — | WO | claimed |
| WO-2011057387-A1 | NITRIC OXIDE AMINO ACID ESTERS FOR THE TREATMENT OF CHRONIC PAIN | ORAL DELIVERY TECHNOLOGY LTD . (CA) | 2011-05-19 | — | — | WO | claimed |
| WO-2011057386-A1 | COMPOSITION AND PROPHYLACTIC DEVICE FOR ENHANCING SEXUAL PERFORMANCE OR PLEASURE | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2011-05-19 | — | — | WO | claimed |
| US-20150202175-A1 | Nitric Oxide Amino Acid Esters for Improving Vascular Circulation, and Prophylaxis or Treatment of a Condition Associated with Impaired Blood Circulation | FARBER MICHAEL (US) | 2015-07-23 | — | — | US | disclosed |
| US-8946160-B2 | Nitric oxide amino acid esters for improving vascular circulation, and prophylaxis or treatment of a condition associated with impaired blood circulation | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2015-02-03 | — | — | US | disclosed |
| US-20130287866-A1 | Nitric Oxide Amino Acid Esters for Improving Vascular Circulation, and Prophylaxis or Treatment of a Condition Associated with Impaired Blood Circulation | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2013-10-31 | — | — | US | disclosed |
| EP-2632453-A1 | NITRIC OXIDE AMINO ACID ESTERS FOR IMPROVING VASCULAR CIRCULATION, AND PROPHYLAXIS OR TREATMENT OF A CONDITION ASSOCIATED WITH IMPAIRED BLOOD CIRCULATION | Oral Delivery Technology Ltd. (CA) | 2013-09-04 | — | — | EP | disclosed |
| US-20120289597-A1 | NITRIC OXIDE AMINO ACID ESTERS FOR THE TREATMENT OF CHRONIC PAIN | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2012-11-15 | — | — | US | disclosed |
| US-8287926-B2 | Combinations of vasoactive agents and their use in the treatment of sexual dysfunctions | INDENA S.P.A. (IT) | 2012-10-16 | — | — | US | disclosed |
| WO-2012088597-A1 | NITRIC OXIDE AMINO ACID ESTERS FOR ENHANCEMENT OF PHYSICAL OR MUSCULAR PERFORMANCE AND THE TREATMENT OF MUSCULAR OR NEUROMUSCULAR DISEASES | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2012-07-05 | — | — | WO | disclosed |
| EP-1644014-A1 | COMBINATIONS OF VASOACTIVE AGENTS AND THEIR USE IN THE TREATMENT OF SEXUAL DYSFUNCTIONS | INDENA S.p.A. (IT) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005004890-A1 | COMBINATIONS OF VASOACTIVE AGENTS AND THEIR USE IN THE TREATMENT OF SEXUAL DYSFUNCTIONS | INDENA S.P.A. (IT) | 2005-01-20 | — | — | WO | disclosed |
| US-20030103915-A1 | Combinations of sunscreens | 3V SIGMA S.P.A. (IT) | 2003-06-05 | — | — | US | disclosed |
| EP-1300137-A2 | Combinations of sunscreens | 3V SIGMA S.p.A (IT) | 2003-04-09 | — | — | EP | disclosed |
| US-6514485-B1 | Combinations of sunscreens | 3V SIGMA S.P.A. (IT) | 2003-02-04 | — | — | US | disclosed |
| EP-1027883-A2 | Combinations of sunscreen agents with UV-A and UV-B filtering properties | 3V SIGMA S.p.A (IT) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999006014-A2 | COMBINATIONS OF SUNSCREENS AND COMPOSITIONS CONTAINING THEM | 3V SIGMA S.P.A. (IT) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202175-A1 | Nitric Oxide Amino Acid Esters for Improving Vascular Circulation, and Prophylaxis or Treatment of a Condition Associated with Impaired Blood Circulation | NOS1, NOS2, NOS3 | ACHE 559/4885ALDH1A1 2382/4885ESR1 1505/4885 |
| US-20130287866-A1 | Nitric Oxide Amino Acid Esters for Improving Vascular Circulation, and Prophylaxis or Treatment of a Condition Associated with Impaired Blood Circulation | NOS1, NOS2, NOS3 | ACHE 572/4885ALDH1A1 2554/4885ESR1 1572/4885 |
| US-20120289597-A1 | NITRIC OXIDE AMINO ACID ESTERS FOR THE TREATMENT OF CHRONIC PAIN | NOS2, NOS3, NOS1 | ACHE 68/4885ALDH1A1 1030/4885ESR1 2034/4885 |
| US-20030103915-A1 | Combinations of sunscreens | ERCC4, ERCC1, ERCC5 | ACHE 3130/4885ALDH1A1 697/4885ESR1 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.